louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06102148: The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson in Patients With Multiple Sclerosis
Official title: The Effect Of Proprioceptive Neuromuscular Facilitation Techniqueson Pain, Motor Functions, Fatique and Health Related Quality of Life in Patients With Multiple Sclerosis: A Randomized, Single-blind Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: Multiple Sclerosis
Proprioceptive Neuromuscular Facilitation
Pain
Motor Function
Fatigue
Quality of Life
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2023-10-26
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to examine the effects of PNF techniques on pain, motor function, fatigue and quality of life.


Eligibility criteria: Inclusion Criteria:

* a clinical diagnosis of Relapsing-Remitting MS (RRMS) as defined by McDonald criteria
* 18-65 years of age
* an Expanded Disability Status Scale (EDSS) score \< 4
* relapse-free for the last 3 months
* cognitive impairment that was defined with mini mental test.

Exclusion Criteria:

* a history of different neurological diseases
* having any contraindication for exercise
* having orthopedic, vision, hearing, or perception problems.

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: through study completion, an average of 1 year
measure: Multiple Sclerosis Quality of Life-54 (MSQoL-54)
timeFrame: through study completion, an average of 1 year
measure: Fatigue Severity Scale and Fatigue Impact Scale (FIS)
timeFrame: through study completion, an average of 1 year
measure: Timed Up and Go (TUG)
timeFrame: through study completion, an average of 1 year
measure: The Six-Minute Walk Test (6-MWT)
timeFrame: through study completion, an average of 1 year
measure: Hand Dexterity
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Ondokuz Mayıs University
Study officials:
References:
Clinical trial NCT00209430: Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
Official title: GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Renal Impairment
Keywords: Iodixanol
Iopamidol
coronary angiography
Contrast media-induced nephropathy
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2005-09-21
Enrollment: 408
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.

Detailed description: GEHC has decided not to provide this detail

Eligibility criteria: Inclusion Criteria:

* Subjects with a combination of diabetes mellitus (type I or II) and renal impairment, defined as serum creatinine (SCr ) ≥150 µmol/L (1.7 mg/dL) for men and ≥133 µmol/L (1.5 mg/dL) for women or creatinine clearance (CrCl) ≤ 50 mL/min calculated according to Cockroft-Gault formula, referred for coronary angiography with or without PCI.

Exclusion Criteria:

* Concurrent administration of potentially nephroprotective or nephrotoxic drugs is not allowed. Subjects undergoing dialysis or kidney transplant will not be included.

Primary outcomes:
measure: Peak increase in SCr
measure: Incidence of contrast media-induced nephropathy from baseline up to day 3.
Secondary outcomes:
measure: SCr concentrations up to days 3 and 7
measure: image quality
measure: occurrence of adverse events and their severity and relationship with the contrast media.
Other outcomes:
Locations:
city: Solna
country: Sweden
facility: Amersham Health S.A
Study officials:
affiliation: GE Healthcare
name: Caroline Widlund, BSc RN
role: STUDY_DIRECTOR
affiliation: 609-514-6809
name: Johnny Gibbs, Jr., B.S., CCRA
role: STUDY_DIRECTOR
References:
citation: Laskey W, Aspelin P, Davidson C, Rudnick M, Aubry P, Kumar S, Gietzen F, Wiemer M; DXV405 Study Group. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J. 2009 Nov;158(5):822-828.e3. doi: 10.1016/j.ahj.2009.08.016.
Clinical trial NCT02663830: The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene
Official title: The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anovulatory
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2016-01-26
Enrollment: 210
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study is to evaluate the effect of sildenafil citrate on the pregnancy rate in women undergoing induction of ovulation using clomiphene citrate.


Eligibility criteria: Inclusion Criteria:

* Women age 21-35 years.
* Anovulatory cycles due to polycystic ovaries syndrome.
* Non-smokers.
* Free of major medical illness

Exclusion Criteria:

* Women with myoma or adenomyosis
* Women with congenital uterine anomaly.
* Chronic use of any medications including non-steroidal anti-inflammatory drugs.
* Associated cases of infertility other than PCOs (male factor, tubal factor,....).
* Asherman syndrome.
* Cases with endometrial hyperplasia.
* Cases with endometrial polyp

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 6 weeks
Secondary outcomes:
measure: endometrial thickness
timeFrame: 2 weeks
measure: miscarriage rate
timeFrame: 13 weeks
measure: ectopic pregnancy rate
timeFrame: 8 weeks
measure: Side Effects of Vasodilators
timeFrame: 4 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06117930: Study of Human Brain-Gut Axis and Gut Microbiome in Patients With Brain Lesions - Repository for Neuroscience Research
Official title: Study of Human Brain-Gut Axis and Gut Microbiome In Patients With Brain Lesions - Repository for Neuroscience Research
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Malignant Central Nervous System Neoplasm
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-11-07
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients undergoing resection for a tumor of the central nervous system and associated controls are eligible to participate in this study.

Brief summary: This study explores how microorganisms in the gut can affect the growth and progression of brain tumors.

Detailed description: PRIMARY OBJECTIVES:

I. To establish a Mayo Clinic Florida Brain Tumor-Gut Axis Human Biorepository by sequential collection of fecal, urine, blood, saliva, and/or tissue samples and clinical patient information.

II. To use spatial transcriptome/proteomics/multi-omics coupled with microbiome data from various sources including brain tissue and stool samples to understand how microbiota could impact disease development, progression, and treatment response in patients with brain cancer.

III. To study the effect of microbiome and potential relationships and/or microbiome reconstruction to impact patient's clinical outcomes including chemo, radiation, immunotherapy and/or cellular therapy.

OUTLINE: This is an observational study.

Participants undergo blood, tissue, saliva, urine and stool sample collection and complete questionnaires on study.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing resection for a tumor of the central nervous system and associated controls are eligible to participate in this study.

Exclusion Criteria:

* Excluded samples will be from patients younger than 18 years old. There are no exclusions due to race/sex.

Primary outcomes:
measure: Establish the Mayo Clinic Florida Tumor-Gut Axis Biorepository
timeFrame: Approximately 1 year, or until samples have been collected based on scheduled treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Alfredo Quinones-Hinojosa, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05672030: Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Official title: Role of Interleukin 5 (IL-5) and IL-5R Signaling in Non-eosinophil Upper Airway Cells in Chronic Rhinosinusitis With Nasal Polyps
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Nasal Polyps
Aspirin-exacerbated Respiratory Disease
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2023-01-05
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: AERD, CRSwNP, healthy controls undergoing planned elective sinus surgery.

Brief summary: The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.

Detailed description: Further characterization of the role of IL-5Rα expression and function on human plasma cells will determine whether inhibiting IL-5 signaling on these cells offers therapeutic promise in other diseases related to plasma cell proliferation. Further characterization of human upper airway epithelial cell IL-5Rα expression and function will determine whether or not inhibiting IL-5 signaling on these cells offers therapeutic promise in other diseases related to epithelial dysfunction. IL-5Rα expression has been identified on several relevant sinus tissue effector cells, including on nasal polyp plasma cells and epithelial cells, and the aim of this study is to further the field by determining the consequences of IL-5 signaling on those cells.

Eligibility criteria: Inclusion Criteria:

* AERD, CRSwNP, healthy controls

Exclusion Criteria:

* Not on any systemic steroids or respiratory biologics at time of surgery

Primary outcomes:
measure: Nasal polyp plasma cell transcriptome
timeFrame: At baseline
Secondary outcomes:
measure: Function of IL-5Ra on nasal polyp plasma cells.
timeFrame: At baseline
measure: IL-5Ra signaling on nasal epithelial cells
timeFrame: At baseline
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Tanya Laidlaw
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03797430: Determination of Normal Values for the Star Excursion Balance Test (SEBT) in Handball Players
Official title: Determination of Normal Values for the Star Excursion Balance Test(SEBT) in National or International Handball Young Women Players
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Handball Players
Keywords: hand ball
evaluation
risk of injury
women
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2019-01-09
Enrollment: 0
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: national or international hanball women players, aged from 14 to 18 years old

Brief summary: the aim of this study is to determine normal values for SEBT in young national or international handball women players for determining specific level for SEBT to predict risk of injury


Eligibility criteria: Inclusion Criteria:

* women
* age from 14 to 18 years old
* national or international level for handball

Exclusion Criteria:

* no french language
* players who don't understand the instructions to perform the test
* Refusal to perform the test

Primary outcomes:
measure: determination of normal values for SEBT
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: CHU Brest
name: Marc BEAUMONT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05724030: Use of Integrated Pulmonary Index Monitorisation in Children Undergoing Botulinum Toxin Injection
Official title: Effect of Integrated Pulmonary Index on Hypoxia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy
Pediatric ALL
Keywords: botilinum toxin
pediatrics
ıntegrated pulmonary index
hypoxia
Lead sponsor: Kocaeli University
Sponsor class: OTHER
First posted: 2023-02-13
Enrollment: 69
Sex: ALL
Minimum age (years): 4
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: This study aimed to detect hypoxia early with ıntegrated pulmonary index monitoring compared to saturation.

Detailed description: This trial will be held at the kocaeli Universty Hospital. 75 children 4-17 years of age undergoing botulinum toxin injection with sedation will be enrolled in this prospective study. Patients premedicated with midasolam iv 0.5 mg bolus and then sedated with propofol 1 mg/kg and fentanyl 0.5 mg/kg . Integrated pulmonary monitoring and noninvasive capnograhy will be used. Bis monitoring and spo2 monitoring will be applied. standard anesthesia monitoring including noninvasive blood pressure, spo2 , ekg and heart rate will be monitored. This trial aimed to detect hypoxia and apnea earlier than pulse oximetry.

Eligibility criteria: Inclusion Criteria:

* 4-16 age pediatrics
* undergoing botilinum injection with sedation
* asa 1-2

Exclusion Criteria:

* \> 18 age
* asa 3-4
* patients with upper respiratory tract infection

Primary outcomes:
measure: hypoxia
timeFrame: 20 seconds
Secondary outcomes:
measure: apnea - ıntegrated pulmonary index
timeFrame: 20 seconds
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli University School of Medicine
Study officials:
References:
Clinical trial NCT04433130: Eye Health in Children and Adolescents: Repeated Cross-sectional Survey
Official title: Eye Health in Children and Adolescents: Repeated Cross-sectional Survey
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Visual Acuity
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
Collaborators: name: Sun Yat-sen University
name: Chinese University of Hong Kong
First posted: 2020-06-16
Enrollment: 300
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects seeking care on refractive error or vision problems and their parents

Brief summary: The investigator will take a mixed-methods approach to gather relevant information from both children or adolescents, and their parents on profiles of eye health, as well as routinely available indicators. This includes a series of baselining and follow-up analyses of cohort data collected on epidemiological, clinical, therapeutic, and service aspects of eye health and individual-level outcomes

Detailed description: The investigator will take a mixed-methods approach to gather relevant information from both children or adolescents, and their parents on profiles of eye health, as well as routinely available indicators. This includes a series of baselining and follow-up analyses of cohort data collected on epidemiological, clinical, therapeutic, and service aspects of eye health (e.g., social environment, preventive behaviours, risk factors, knowledge and attitudes, health and social care, etc.) and individual-level outcomes (e.g., clinical parameters and symptoms, biomarkers, self-reported measures, risk profiles, etc.).

Eligibility criteria: Inclusion:

* Subjects with valid information on eye health-related profiles
* Completion of eye health examination delivered by trained ophthalmic professionals

Exclusion:

* Inability to give informed consent
* Unable to retrieve individual records on eye health examination

Primary outcomes:
measure: visual acuity
timeFrame: Baseline and changes up to 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-sen University
state: Guangdong
Study officials:
References:
Clinical trial NCT02510430: The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors
Official title: Randomized Controlled Trial of Sitting Time Interventions in Breast Cancer Survivors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Neoplasms
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2015-07-29
Enrollment: 59
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Excessive sitting time (sedentary time) has been associated with risk of insulin resistance and other factors which may be relevant to breast cancer prognosis. This 8-week study tests different strategies for helping breast cancer survivors to modify their levels of sitting time. Participants will be assigned with equal likelihood to one of three groups (1) overall reduction in sitting time, (2) interruption of sitting time with standing breaks, and (3) usual care.


Eligibility criteria: Inclusion Criteria:

1. diagnosed with Stage 0-III breast cancer. Bilateral or multiple primary breast cancers are permitted.
2. Completed primary treatment defined as definitive surgery, (neo)adjuvant chemotherapy and/or (neo)adjuvant radiation. Participants still receiving adjuvant endocrine or HER2 targeted therapies are eligible.
3. Report sitting for ≥8 accumulated waking hours on a typical day,
4. Willing and able to attend 3 study visits at the UW,
5. Willing to attempt reduction of sitting time,
6. Use the internet on a regular basis,
7. Willing and able to complete study requirements, and
8. Currently considered postmenopausal (no menstrual periods in past 12 months), even if pre-menopausal at diagnosis.

Exclusion Criteria:

1. Evidence of recurrence or metastatic disease,
2. Unable to move from sitting to standing without difficulty and to walk 1 block.

Primary outcomes:
measure: Feasibility as measured by recruitment and retention rates
timeFrame: 12 months
Secondary outcomes:
measure: Sedentary behavior as measured by ActivPal
timeFrame: 7 days
measure: Physical activity as measured by ActiGraph
timeFrame: 7 days
measure: Sedentary time as measured by ActiGraph
timeFrame: 7 days
Other outcomes:
Locations:
city: Madison
country: United States
facility: UW Hospital
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Lisa A Cadmus-Bertram, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01742130: Early Hydration in Acute Myocardial Infarction
Official title: Early Hydration in Acute Myocardial Infarction: Sodium Bicarbonate Versus Saline for the Prevention on Contrast-induced Acute Kidney Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Contrast Induced Acute Kidney Injury
Keywords: Contrast-induced nephropathy
Contrast media
Angiography
Coronary percutaneous intervention
Lead sponsor: Ospedale Misericordia e Dolce
Sponsor class: OTHER
First posted: 2012-12-05
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether hydration with sodium bicarbonate is more effective than hydration with sodium chloride to prevent contrast nephropathy in patients undergoing primary coronary intervention for acute ST elevation myocardial infarction.


Eligibility criteria: Inclusion Criteria:

* Consecutive patients with AMI candidates for primary PCI presenting within 12 h of symptom onset with ST-segment elevation of more 1 mm in at least two contiguous leads of electrocardiogram.

Exclusion Criteria:

* contrast medium administration within the 10 days
* end-stage renal failure requiring dialysis
* refusal to give informed consent

Primary outcomes:
measure: Incidence of contrast-induced acute kidney injury
timeFrame: 2 days
Secondary outcomes:
measure: adverse clinical events
timeFrame: 1 month
Other outcomes:
Locations:
city: Prato
country: Italy
facility: Ospedale Misericordia e Dolce
Study officials:
References:
Clinical trial NCT02477930: Endosponge Vacuum Therapy (E-VAC) Registry of Intestinal Anastomotic Leaks and Perforations
Official title: Prospective Registry The Treatment Of Upper And Lower Intestinal Anastomotic Leaks And Perforations
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intestinal Anastomotic Leak
Intestinal Perforations
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
First posted: 2015-06-23
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient's with upper and lower intestinal anastomotic leaks and perforations who are referred for E-Vac therapy or are the primary patients of Dr. Leeds and Dr. Burdick will be invited to participate in this registry.

Brief summary: The purpose of this registry is to collect data on the clinical use of endoluminal vacuum (E-Vac) therapy to treat both upper and lower intestinal leaks and perforations.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing E-Vac Therapy
* Age \> 17 years

Exclusion Criteria:

* 17 years of age or younger
* Undergone an E-Vac placement \> 14 days before consenting

Primary outcomes:
measure: In-Hospital survival-rate
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Baylor University Medical Center
state: Texas
Study officials:
affiliation: Baylor Health Care System
name: Steven Leeds, MD
role: PRINCIPAL_INVESTIGATOR
References: